A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Peripheral T-cell Lymphoma (PTCL) PTCL-001
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
University of Virginia - Charlottesville
Start Date
May 1, 2024
End Date
July 31, 2024
Administered By
Duke Cancer Institute
Awarded By
University of Virginia - Charlottesville
Start Date
May 1, 2024
End Date
July 31, 2024